Nanoform Finland Oyj (NANOFH.HE)
EUR 1.29
(2.7%)
EUR 1.29
(2.7%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 5.2 Million EUR | -11.75% |
| 2022 | 5.89 Million EUR | -11.88% |
| 2021 | 6.69 Million EUR | 13.57% |
| 2020 | 5.89 Million EUR | 85.71% |
| 2019 | 3.17 Million EUR | 43.48% |
| 2018 | 2.21 Million EUR | 204.39% |
| 2017 | 726.34 Thousand EUR | 113.01% |
| 2016 | 340.99 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 4.84 Million EUR | 0.0% |
| 2024 Q1 | 5.01 Million EUR | 0.0% |
| 2023 Q2 | 5.47 Million EUR | -4.37% |
| 2023 FY | 5.2 Million EUR | -11.75% |
| 2023 Q4 | 5.2 Million EUR | -1.11% |
| 2023 Q3 | 5.26 Million EUR | -3.82% |
| 2023 Q1 | 5.72 Million EUR | -2.97% |
| 2022 Q1 | 6.48 Million EUR | -3.02% |
| 2022 Q4 | 5.89 Million EUR | -3.22% |
| 2022 Q3 | 6.09 Million EUR | -3.26% |
| 2022 Q2 | 6.29 Million EUR | -2.96% |
| 2022 FY | 5.89 Million EUR | -11.88% |
| 2021 FY | 6.69 Million EUR | 13.57% |
| 2021 Q4 | 6.69 Million EUR | 0.66% |
| 2021 Q3 | 6.64 Million EUR | 43.72% |
| 2021 Q2 | 4.62 Million EUR | -18.79% |
| 2021 Q1 | 5.69 Million EUR | -3.33% |
| 2020 FY | 5.89 Million EUR | 85.71% |
| 2020 Q2 | 4.75 Million EUR | 0.66% |
| 2020 Q4 | 5.89 Million EUR | -1.34% |
| 2020 Q3 | 5.97 Million EUR | 25.6% |
| 2020 Q1 | 4.72 Million EUR | 48.89% |
| 2019 Q4 | 3.17 Million EUR | 0.0% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 FY | 3.17 Million EUR | 43.48% |
| 2018 FY | 2.21 Million EUR | 204.39% |
| 2017 FY | 726.34 Thousand EUR | 113.01% |
| 2016 FY | 340.99 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Biohit Oyj | 400 Thousand EUR | -1200.843% |
| Herantis Pharma Oyj | 29.84 Thousand EUR | -17334.065% |